SEARCH

SEARCH BY CITATION

References

  • Birnbaumer L., Abramowitz J. and Brown A. M. (1990) Receptor-effector coupling by G-proteins. Biochim. Biophys. Acta 1031, 163224.
  • Black J. W. and Leff P. (1983) Operational models of pharmacological agonism. Proc. R. Soc. Lond. B 220, 141162.
  • Cavalli A., Fanelli F., Taddei C., De Benedetti P. G. and Cotecchia S. (1996) Amino acids of the α1B adrenergic receptor involved in agonist binding: differences in docking catecholamines to receptor subtypes. FEBS Lett. 399, 913.
  • Coley C., Woodward R., Johansson A. M., Strange P. G. and Naylor L.H. (2000) The effect of multiple serine/alanine mutations in TMV of theD2 dopamine receptor. J. Neurochem. 74, 358366.
  • Colquhoun D. (1998) Binding, gating and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br. J. Pharmacol. 125, 924947.
  • Cox B. A., Henningsen R. A., Spanoyannis A., Neve R. L. and Neve K.A. (1992) Contributions of conserved serine residues to the interactionsof ligands with dopamine D2 receptors. J. Neurochem. 59, 627635.
  • DeLean A., Stadel J. M. and Lefkowitz R. J. (1980) A ternary complex model explains the agonist specific binding properties of the adenylyl cyclase-coupled β-adrenergic receptor. J. Biol. Chem. 255, 71087117.
  • Evans T., Hepler J. R., Masters S. B., Brown J. H. and Harden T. K. (1985) Guanine nucleotide regulation of agonist binding to muscarinic acetylcholine receptors. Biochem. J. 232, 751757.
  • Fitzgerald L. W., Conklin D. S., Krause C. M., Marshall A. P., Patterson J. P., Tran D. P., Iyer G., Kostich W. A., Largent B. L. and Hartig P.R. (1999) High affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5HT2a and 5HT2c receptors: evidence favouring the ternary complex and two state models of agonist action. J. Neurochem. 72, 21272134.DOI: 10.1046/j.1471-4159.1999.0722127.x
  • Gardner B. and Strange P. G. (1998) Agonist action at D2 (long) dopamine receptors: ligand binding and functional assays. Br. J. Pharmacol. 124, 978984.
  • Gardner B. R., Hall D. A. and Strange P. G. (1996) Pharmacological analysis of dopamine stimulation of [35S]GTPγS binding via human D2short and D2long dopamine receptors expressed in recombinant cells. Br. J. Pharmacol. 118, 15441550.
  • Gardner B. R., Hall D. A. and Strange P. G. (1997) Agonist action at D2(short)dopamine receptors determined in ligand binding and functional assays. J. Neurochem. 69, 25892598.
  • Harley E. A., Middlemiss D. M. and Ragan C. I. (1995) Relationship between inhibition of cAMP production in Chinese hamster ovary cells expressing the rat D2(444) receptor and antagonist/agonist binding ratios. Br. J. Pharmacol. 115, 13071313.
  • Hausdorff W. P., Hnatowitch M., O'Dowd B. F., Caron M. G. and Lefkowitz R. J. (1990) A mutation of the β2-adrenergic receptor impairs agonist activation of adenylyl cyclase without affecting high affinity agonist binding: distinct molecular determinants of the receptor are involved in physical coupling to and functional activation of Gs. J. Biol. Chem. 265, 13881393.
  • Hayes G., Biden T. J., Selbie L. A. and Shine J. (1992) Structural subtypes of the dopamine D2 receptor are functionally distinct: expression of cloned D2A and D2B subtypes in a heterologous cell line. Mol. Endocrinol. 6, 920926.
  • Hwa J. and Perez D. M. (1996) The unique nature of the serine interactions for α1-adrenergic receptor agonist binding and activation. J.Biol. Chem. 271, 63226327.
  • Lahti R. A., Figur L. M., Piercey M. F., Ruppel P. L. and Evans D. L. (1992) Intrinsic activity determinations at the dopamine D2 guanine nucleotide binding protein coupled receptor. Utilisation of receptor state binding affinities. Mol. Pharmacol. 42, 432438.
  • Lefkowitz R. J., Cotecchia S., Samama P. and Costa T. (1993) Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol. Sci. 14, 303307.
  • Liapakis G., Ballesteros J. A., Papachristou S., Chan W. C., Chen X. and Javitich J. A. (2000) The forgotten serine. A critical role for Ser 203 in ligand binding to and activation of the β2 adrenergic receptor. J. Biol. Chem. 275, 3777933788.
  • Malmberg A., Nordvall G., Johansson A. M., Mohell N. and Hacksell U. (1994) Molecular basis for the binding of 2-aminotetralins to human dopamine D2A and D3 receptors. Mol. Pharmacol. 46, 299312.
  • Malmberg A., Mohell N., Backlund Hook B., Johansson A. M., Hacksell U. and Nordvall G. (1998) Interactions of ligands with active and inactive conformations of the dopamine D2 receptor. Eur. J. Pharmacol. 346, 299307.
  • Mansour A., Meng F., Meador-Woodruff J. H., Taylor L. P., Civelli O. and Akil H. (1992) Site-directed mutagenesis of the human dopamine D2 receptor. Eur. J. Pharmacol. 227, 205214.
  • Salomon Y., Londos C. and Rodbell M. (1974) A highly sensitive adenylate cyclase assay. Anal. Biochem. 58, 541548.
  • Samama O., Cotecchia S., Costa T. and Lefkowitz R. J. (1993) A mutation induced activated state of the β2-adrenergic receptor. J.Biol. Chem. 268, 46254636.
  • Seeman P., Watanabe M., Grigoriadis D., Tedesco J. L., George S. R., Svensson U., Lars J., Nilsson G. and Neumeyer J. L. (1985) Dopamine D2 receptor binding sites for agonists. A tetrahedral model. Mol. Pharmacol. 28, 391399.
  • Sibley D. and Creese I. (1983) Interaction of ergot alkaloids with anterior pituitary D2 dopamine receptors. Mol. Pharmacol. 23, 585593.
  • Strader C. D., Candelore M. R., Hill W. S., Sigal I. S. and Dixon R. A. F. (1989) Identification of two serine residues involved in agonist activation of the β-adrenergic receptor. J. Biol. Chem. 264, 1357213578.
  • Strange P. G. (1996a) The energetics of ligand binding to catecholamine receptors. Trends Pharmacol. Sci. 17, 235271.
  • Strange P. G. (1996b) 7TM receptors: locks and keys. Trends Pharmacol. Sci. 17, 346.
  • Strange P. G. (1999) G-protein coupled receptors – conformations and states. Biochem. Pharmacol. 58, 10811089.
  • Van Koppen C. J., Sell H., Lenz W. and Jakobs K. H. (1994) Deletion analysis of the m4 muscarinic receptor. Molecular determinants for activation of but not coupling to guanine nucleotide binding regulatory protein regulate receptor internalisation. Eur. J. Biochem. 222, 525531.
  • Wang C., Buck M. A. and Fraser C. M. (1991) Site-directed mutagenesis of α2a-adrenergic receptors: identification of amino acids involved in ligand binding and receptor activation by agonists. Mol. Pharmacol. 40, 168179.
  • Weiss J. M., Morgan P. H., Lutz M. W. and Kenakin T. P. (1996) The cubic ternary complex receptor occupancy model. J. Theor. Biol. 181, 381397.
  • Wilson J., Lin H., Fu D., Javitch J. A., and Strange P. G. (2001) Mechanism of inverse agonism of antipsychotic drugs at the D2 dopamine receptor: use of a mutant receptor that adopts the activated conformation. J. Neurochem. 77, 493504.DOI: 10.1046/j.1471-4159.2001.00233.x
  • Wreggett K. A. and DeLean A. (1984) The ternary complex model: its properties and applications to ligand interactions with the D2 dopamine receptor of the anterior pituitary gland. Mol. Pharmacol. 26, 214227.